A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS
Completed · Phase 1
Conditions studied: Respiratory Distress Syndrome, Adult
In brief
A Phase 1 study of agenT-797 to treat moderate to severe acute respiratory syndrome in Coronavirus disease 2019 (COVID-19) participants.
Key facts
- Study ID
- NCT04582201
- Run by
- MiNK Therapeutics
- People needed
- 20
- Starts
- 2020-09-21
- Expected to finish
- 2023-04-23
- Last updated by the study team
- 2025-12-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Voluntarily agree to participate and ability to provide informed consent or have duly appointed health care proxy with the authority to consent.
- Confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by polymerase chain reaction test or equivalent approved test.
- Inpatient hospitalization.
- Evidence of SARS-CoV-2 infection with the diagnosis of moderate to severe ARDS per Berlin definition, no more than 2 weeks prior to study enrollment.
- Participants, or duly appointed health care proxy with the authority to consent, must consent to placement of a central venous access line for the administration of agenT-797.
You may not qualify if…
- Currently participating and receiving study therapy of an investigational agent that is not registered for any other indication. Note: Participants may receive the standard of care for SARS-CoV-2 infection as per institutional practices.
- Presence of comorbidities limiting expected survival of <1 month.
- Any comorbidity which in the opinion of the investigator may preclude/confound study required safety and efficacy assessments.
- Clinically significant cardiomyopathy.
- Receipt of non-oncology vaccines containing live virus for prevention of infectious diseases within 4 weeks prior to first dose of study treatment.
- Known hypersensitivity to natural killer cells or their preservation solution.
- Active systemic bacterial or fungal infection or viral co-infection.
- Legally incapacitated or has limited legal capacity.
- Pregnant or lactating women.
Where it is running
- Saint John's Cancer Institute — Santa Monica, California, United States
- Norton Cancer Institute, St. Matthews Campus — Louisville, Kentucky, United States
- Weill Cornell Medicine New York Presbyterian — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.